Anavex Life Sciences Corp (AVXL)

[Steady_T]

I'm pretty sure that what you are saying is not true. Anavex found that the mutant type of the Sr1 receptor had a lesser response to 2-73. However a lesser response in not nearly the same as no response which is what you are suggesting.

Missling stated that at the high dose the mutant type patients responded nearly as well as the wild type patients.

Your suggestion that selling 2-73 to those patients would be unethical is pure unadulterated BS.